CDMO & CDRO Integrated Collaboration
[PharmNews] BXPLANT announced on the 26th that it has signed a strategic business cooperation agreement with Protium Science for collaboration in CDMO (Contract Development and Manufacturing Organization) and CDRO (Contract Development and Research Organization) services.
Through this agreement, both companies plan to establish a close CDMO and CDRO cooperation system based on the technologies and know-how accumulated in their respective fields, and to continuously combine their capabilities moving forward.
BXPLANT is a specialist company in the bio healthcare sector focusing on Scalerator & CDRO (Clinical Development and Research Organization) services. Through full-cycle new drug development services including R&D strategy consulting, licensing and registration, and clinical trials, the company increases the success rate of early-stage clinical development and accelerates technology commercialization. Additionally, it serves as a platform for corporate growth and open innovation through identifying promising startups, facilitating investment attraction, and supporting global expansion.
Protium Science, a specialist CDAO (Contract Development and Analysis Organization) company for biopharmaceuticals, is a subsidiary of KOSDAQ-listed new drug developer Tium Bio. Protium Science provides comprehensive services from cell line development for biopharmaceutical production to upstream process development services required for API (Active Pharmaceutical Ingredient) and finished drug product manufacturing, as well as consulting on documentation preparation for clinical trial applications and regulatory agency response materials.
Minkeun Jo, CEO of BXPLANT, stated, “Through this cooperative framework, we can now link CDAO & CDMO services,” adding, “Moving forward, we will be able to provide integrated clinical development solutions to clients with excellent technologies.”
Yongho Ahn, CEO of Protium Science, stated, “Through this business agreement, we will strengthen close business cooperation between both companies to not only provide various services required for drug development under optimal conditions, but also establish a new model that can perfectly meet the needs of our clients.”
source : BXPLANT Signs Strategic Partnership Agreement with Protium Science, Tae-il Kim, Pharm News, 2024.03.26., https://www.pharmnews.com/news/articleView.html?idxno=241568
